Artificial Cells Nanomedicine and Biotechnology

Our screening does not flag Artificial Cells Nanomedicine and Biotechnology. That is not a guarantee of quality — it means the venue is not on Beall's archive (frozen since 2017) and does not match our name-pattern heuristic. It is listed in DOAJ, Scopus, Web of Science, PubMed, which is a positive signal.

Per our venue index, Artificial Cells Nanomedicine and Biotechnology appears in: DOAJ, Scopus, Web of Science, PubMed. Index membership changes over time — confirm on the index's own site before relying on it.

Papers in Artificial Cells Nanomedicine and Biotechnology are cited about 4.7 times each within two years of publication, and Scimago places it in Q1, with an h-index of 114. Those are the open equivalents: the Clarivate Journal Impact Factor is a proprietary metric we neither compute nor license, so we show the two-year citation rate and Scimago quartile instead — they answer the same question of how heavily the journal is cited. A citation rate is a property of a field as much as of a journal.

In the Scimago Journal Rank 2025 edition, Artificial Cells Nanomedicine and Biotechnology is Q1 in 3 of its 4 subject categories and Q2 in the other 1. By category: Pharmaceutical Science: Q1, #30 of 195; Biotechnology: Q1, #79 of 320; Medicine (miscellaneous): Q1, #546 of 2,517; Biomedical Engineering: Q2, #84 of 328. Its best category quartile is Q1. Quartiles split the journals in a subject category into four equal groups by SJR, so Q1 is the most-cited quarter and Q4 the least; Artificial Cells Nanomedicine and Biotechnology is cited about 4.7 times per paper over two years, with an h-index of 114.

The Web of Science quartile comes from Clarivate's Journal Citation Reports (JCR), a proprietary product we neither license nor compute — so we cannot state a JCR quartile for Artificial Cells Nanomedicine and Biotechnology. The open equivalent is its best Scimago quartile, Q1 in Pharmaceutical Science and 2 other categories, derived from Scopus citation data. Because JCR ranks against Web of Science and Scimago against Scopus, the two can differ, so check Clarivate's site directly if you need the JCR quartile specifically.

Our index records its access status as "gold". Where this is derived from publisher-level signals rather than works-level data it is a heuristic, so confirm on the journal's own site — particularly if an article processing charge matters to you.

Article processing charge (APC): €2,875 per accepted article (DOAJ). Fee waivers are available. The exact charge can vary by article type and any fee waiver, so confirm the current amount on the journal's own site.

Submission to publication for Artificial Cells Nanomedicine and Biotechnology takes about ~20 wk — DOAJ self-reported. Treat it as indicative rather than a guarantee: editorial times vary by article type, reviewer availability and season, and a self-reported figure is the journal's own. We do not hold a peer-review acceptance rate for Artificial Cells Nanomedicine and Biotechnology.